NeuroBo Pharmaceuticals, Inc.

NasdaqCM:NRBO Stock Report

Market Cap: US$20.9m

NeuroBo Pharmaceuticals Valuation

Is NRBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NRBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NRBO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NRBO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRBO?

Key metric: As NRBO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NRBO. This is calculated by dividing NRBO's market cap by their current book value.
What is NRBO's PB Ratio?
PB Ratio1.6x
BookUS$12.95m
Market CapUS$20.85m

Price to Book Ratio vs Peers

How does NRBO's PB Ratio compare to its peers?

The above table shows the PB ratio for NRBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
SPRB Spruce Biosciences
0.4x-7.9%US$21.2m
GLYC GlycoMimetics
1.8x10.5%US$18.5m
UBX Unity Biotechnology
1.4x55.2%US$20.1m
PIRS Pieris Pharmaceuticals
1.4xn/aUS$22.2m
NRBO NeuroBo Pharmaceuticals
1.6x-7.1%US$20.9m

Price-To-Book vs Peers: NRBO is expensive based on its Price-To-Book Ratio (1.6x) compared to the peer average (1.3x).


Price to Book Ratio vs Industry

How does NRBO's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
NRBO 1.6xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NRBO is good value based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is NRBO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRBO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NRBO's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NRBO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.35
US$26.67
+1,034.8%
59.5%US$48.00US$10.00n/a3
Nov ’25US$2.67
US$26.67
+898.8%
59.5%US$48.00US$10.00n/a3
Oct ’25US$2.93
US$26.67
+810.1%
59.5%US$48.00US$10.00n/a3
Sep ’25US$3.69
US$26.67
+622.7%
59.5%US$48.00US$10.00n/a3
Aug ’25US$3.78
US$27.67
+631.9%
56.5%US$48.00US$10.00n/a3
Jul ’25US$4.54
US$27.67
+509.4%
56.5%US$48.00US$10.00n/a3
Jun ’25US$3.81
US$27.67
+626.2%
56.5%US$48.00US$10.00n/a3
May ’25US$3.68
US$36.50
+891.8%
31.5%US$48.00US$25.00n/a2
Apr ’25US$4.06
US$36.50
+799.0%
31.5%US$48.00US$25.00n/a2
Mar ’25US$6.24
US$36.50
+484.9%
31.5%US$48.00US$25.00n/a2
Feb ’25US$5.47
US$36.50
+567.3%
31.5%US$48.00US$25.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies